Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

The enrollment target of this global study is 400 patients.

Marginal Zone Lymphoma (MZL)

  • PCYC-1121: Phase II study of IMBRUVICA in patients with R/R marginal zone lymphoma was initiated in the fourth quarter of 2013. This is a multi center, open-label, monotherapy study to evaluate the safety and efficacy of IMBRUVICA in patients with R/R marginal zone lymphoma. The primary endpoint of this study is overall response rate and the enrollment target of this study is 60 patients.
  • Waldenstrom's Macroglobulinemia (WM)

  • PCYC-1127: Phase III study of IMBRUVICA or placebo in combination with rituximab in patients with previously treated WM was initiated in the second quarter of 2014. This is a randomized, multi-center, double-blinded, placebo-controlled trial of IMBRUVICA.  The primary outcome measure of this study is PFS. The secondary outcome measures include ORR, time to next treatment, OS and number of participants with AEs as a measure of safety and tolerability within each treatment arm. The enrollment target of this study is 180 patients.
  • Multiple Myeloma (MM)

  • PCYC-1111: Phase II study of IMBRUVICA in patients with R/R multiple myeloma was initiated in the first quarter of 2012. This is a Phase II, multi-center, open-label trial designed to assess the safety and efficacy of IMBRUVICA as a single agent and in combination with dexamethasone in patients with R/R MM. At this time, an expansion of cohorts 1, 2 and 3 (420mg, 560mg with dexamethasone, and 840mg) is not planned due to the fact that the protocol-defined response rate was not achieved. The Company has expanded the fourth and final dosing cohort to 43 patients (840mg with dexamethasone) as it crossed a minimum pre-defined boundary of efficacy. The clinical development focus of IMBRUVICA in this indication will be in combination therapies.
  • PCYC-1119: Phase I/IIb study of IMBRUVICA in combination with carfilzomib in patients wi
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

    Related medicine technology :

    1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
    2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
    3. WuXi PharmaTech to Partner with Pharmacyclics
    4. Pharmacyclics Reports Third Quarter 2013 Results
    5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
    6. Pharmacyclics Reports Second Quarter 2013 Results
    7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    8. Pharmacyclics Reports First Quarter 2013 Results
    9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
    (Date:5/4/2015)... N.J. , May 4, 2015  Oncobiologics, ... commercializing monoclonal antibody (mAb) biosimilars, has completed the ... at its headquarters in Cranbury, New ... Cranbury facility is designed to utilize ... manufacturing at commercial scale.  Through the use of ...
    (Date:5/4/2015)... N.Y. , May 4, 2015  Clinical ... Englert , PharmD, has completed preliminary analysis of ... and Schizophrenia. Resources from Clinical Support Services, Inc. ... Reviews (CMR) with patients currently taking psychiatric medications ... The research found that 93% of patients experienced ...
    Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
    ... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, ... and incorrect application of the efficacy assessment protocol. With this ... dyskinesia symptoms at end of two weeks of active treatment ...
    ... treatment may target hunger at its source, another uses ... stomach and suppress hunger and a third explores the ... Initial results from all these studies were reported at ... in San Francisco, Calif. (Logo: ...
    Cached Medicine Technology:Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 2Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 4Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 5Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 6Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 7No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 2No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 3No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 4No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 5No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 6
    (Date:5/4/2015)... (PRWEB) May 04, 2015 Takeda Pharmaceuticals ... billion to settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ... increases the risk that a patient will develop bladder ... 28th, if 95% of those eligible for the Actos ... 9,000 bladder cancer cases currently pending in courts around ...
    (Date:5/4/2015)... NY (PRWEB) May 04, 2015 ... insurance programs, announces the expansion of coverage for its ... a leading provider of industry-tailored insurance and proactive risk ... & Company, we are dedicated to providing our customers ... meet their many evolving needs. We are excited to ...
    (Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
    (Date:5/4/2015)... 04, 2015 TROY Healthcare Solutions is ... Atlantic Regional User Group (RUG) Conference in Baltimore, MD ... Atlantic Regional User Group provides an opportunity for clients ... the exhibitor gallery. , In addition to sponsoring the ... Cerner North Atlantic RUG Conference. Attendees can stop by ...
    (Date:5/4/2015)... (PRWEB) May 04, 2015 The American ... critical state policy reports which identify gaps in coverage ... “After ATA issued the State Telemedicine Gaps Reports last ... how their laws and regulations impact healthcare delivery in ... a result of state actions across the nation, ATA ...
    Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3
    ... The American Academy of Cosmetic Surgery (AACS) 2006 Consumer Perspective ... US citizens have had cosmetic surgery//, a great number are ... ,Jeff Knezovich, executive vice president of the American Academy ... lot since the 1970s when such surgery was rarely mentioned. ...
    ... 200 children were taken ill after eating lunch at their ... were admitted to a hospital and are reportedly in a ... Dianshi Town High School began reporting symptoms of headache, stomach ... Monday and were immediately hopitalised. ,The food samples ...
    ... Health and Family Welfare Minister Anbumani Ramadoss today officially ... The highly contagious disease was prevalent among tribals living ... Last year it was leprosy and this year it ... that India had moved closer to completely eliminating yaws ...
    ... Children are being exposed to the risk of liver damage ... lead and cadmium found in plastic and other soft toys ... ,"Dangerous levels of lead and cadmium have been found ... the markets," said Toxics Link, an environmental non-governmental organisation, in ...
    ... that caused by hay fever and other allergies, have ... without allergies, according to a report in the September ... issue on sleep. ,Allergic rhinitis, which occurs ... nasal passages, affects about 20 to 50 percent of ...
    ... bottles of Similac Infant Formula were off the shelf, after ... following a suspected flaw in the bottle. No repercussions after ... the company has decided to recall the product in order ... C content in the bottle. ,Given ...
    Cached Medicine News:Health News:Dangers Lurking in Soft, Cuddly Toys 2Health News:Allergic Rhinitis Associated with Impaired Sleep Quality 2
    ... has a complete offering of cardiology catheters. ... these catheters are designed with excellent torque, ... and better push-ability, and large inner lumens ... 5, 6 and 7 French sizes with ...
    Used to negotiate tortuous vessels....
    Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
    Used to negotiate tortuous vessels....
    Medicine Products: